Trial Profile
An open-label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study comparing pharmacokinetic and pharmacodynamic effects of Neutrogen (Filgrastim) of Virchow Biotech, India with that of Neupogen (filgrastim) of Roche following 5 mcg/kg subcutaneous injection in healthy, adult human subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Aug 2016
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Virchow Group
- 26 Aug 2016 New trial record